Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q1 FY21 Earnings Presentation
18 slides from Jubilant Pharmova's earnings presentation, Sep 4, 2020
Slide 1: Financial Results Quarter Ended June 30, 2020
Financial Results Quarter Ended June 30, 2020
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : September 04, 2020 Time : 05:00 pm IST Replay: September 04 to September 11, 2020 Dial-in: +91 22 7194 5757/ +91 22 66635757 Playback ID: 55541# 22
Slide 4: Chairmen’s Message
Chairmen’s Message JUBILANT Q1’FY21 PERFORMANCE Q1’FY21 Revenue at Rs 1,893 Crore vs. Rs 2,182 Crore in Q1’FY20; Q1’FY21 EBITDA at Rs 310 Crore vs. Rs 444 Crore in Q1’FY20 Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubi
Slide 5: Update on Reorganization Proposal
Update on Reorganization Proposal Post the board approval on Oct 25, 2019 for reorganizing the businesses of the Company, in November 2019 the Company had filed with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) the Composite Scheme of Arrangement for amalgamation of certain
Slide 6: Q1’FY21 Results Analysis
Ww Mirescncts Q1’FY21 Results Analysis
Slide 7: JLL – Q1’FY21 Financial Highlights
JLL – Q1’FY21 Financial Highlights 1 YoY Particulars Q1'FY20 Q1'FY21 Change (%) Revenue Revenue at Rs 1,893 Crore, as compared with Rs 2,182 Crore in Q1’FY20 Pharmaceuticals2 1,328 1,096 (18%) • Pharmaceuticals revenue at Rs 1,096 Crore as compared to Rs 1,328 Life Science Ingredients 805 737 (9%)
Slide 8: Adjusted Earnings
Adjusted Earnings Rs Crore % Change S. No. Particulars Q1'FY20 Q1'FY21 YoY 1 Reported EBITDA 444 310 (30%) 2 One-off Adjustments 34 8 3 Adjusted EBITDA 478 318 (34%) 4 Reported EBITDA Margin 20.4% 16.4% 5 Adjusted EBITDA Margin 21.9% 16.8% One-off Expenses S. No. Particulars Q1'FY20 Q1'FY21 1 Site R
Slide 9: Pharmaceuticals Segment Highlights – Q1’FY21 (1/2)
Pharmaceuticals Segment Highlights – Q1’FY21 (1/2) Pharmaceuticals revenue was at Rs 1,096 Crore vs. Rs 1,328 Crore in Q1’FY20 Particulars1 Q1'FY20 Q1'FY21 % Change Revenue 1,328 1,096 (18%) Specialty Pharmaceuticals2 Specialty Pharma 725 534 (26%) • Radiopharma business revenue was impacted by de
Slide 10: Pharmaceuticals Segment Highlights – Q1’FY21 (2/2)
Pharmaceuticals Segment Highlights – Q1’FY21 (2/2) USFDA Inspection Details Generics1 • Revenue growth during the quarter was led by strong performance in the US Facility Last Inspection market driven by certain key products Montreal, CMO May, 2018 • With regard to regulatory compliance status of ou
Slide 11: LSI Segment Highlights – Q1’FY21
LSI Segment Highlights – Q1’FY21 Particulars1 Q1'FY20 Q1'FY21 % Change LSI revenue was at Rs 737 Crore against Rs 805 Crore in Q1’FY20. Strong Revenue 805 737 (8%) growth witnessed in Nutritional Products business though Specialty Specialty Intermediates 279 260 (7%) Intermediates and Life Science
Slide 12: Jubilant Biosys – Q1’FY21
Jubilant Biosys – Q1’FY21 Drug Discovery & Development Solutions (DDDS) comprises Particulars1 Q1'FY20 Q1'FY21 % Change Revenue 48 60 26% • Drug Discovery Services business through Jubilant Biosys Limited Drug Discovery Services 48 60 26% provides innovation and collaborative research through two
Slide 13: Proprietary Drug Discovery (Jubilant Therapeutics)
Proprietary Drug Discovery (Jubilant Therapeutics) Jubilant Therapeutics is a patient-focused biopharmaceutical company working to address unmet medical needs in oncology and autoimmune diseases. Our advanced discovery engine integrates structure-based design and computational architecture to disc
Slide 14: Debt Profile
Debt Profile Particulars 31/03/20 30/06/20 Foreign Currency Loans ($ Mn) ($ Mn) Subsidiaries 431 435 Total 431 435 Rupee Loans (Rs. Crs) (Rs. Crs) Standalone 1,295 985 Subsidiaries 100 160 Total 1,395 1,145 Gross Debt (Rs. Crs) (Rs. Crs) Standalone 1,295 985 Subsidiaries 3,361 3,444 Total 4,656 4,42
Slide 15: Business outlook
Business outlook We have seen substantial improvement in demand in most of our business segments from June 2020 onwards be it Specialty Pharma, CMO, API or Specialty Intermediates Given the strong demand recovery and new business sign-ups, we believe COVID-19 is not likely to have a material imp
Slide 16: Appendix
Ww Mirescncts Appendix 15
Slide 17: Income Statement – Q1’FY21
Income Statement – Q1’FY21 Particulars1 Q1'FY20 Q1'FY21 YoY Growth Total Revenue from Operations 2,182 1,893 (13%) Pharmaceuticals 1,328 1,096 (18%) Life Science Ingredients 805 737 (9%) Drug Discovery & Development Solutions 48 60 26% Total Expenditure 1,747 1,602 (8%) Other Income 10 7 Segment EBI
Slide 18: For more information
For more information For Investors: Hemant Bakhru | Pavleen Taneja Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1002| 21 Ph: +91 22 6645 1209 E-mail: hemant.bakhru@jubl.com E-mail: siddharth@cdr-india.com pavleen.taneja@jubl.com For Media: Sudhakar Safaya Desiree Cras